Ista Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ISTA)

Previous CloseN/A
Today's RangeN/A
52-Week RangeN/A
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A

About Ista Pharmaceuticals (NASDAQ:ISTA)

Ista Pharmaceuticals logoISTA Pharmaceuticals, Inc. (ISTA) is a commercial-stage, multi-specialty pharmaceutical company. The Company is engaged in developing, marketing and selling its own products in the United States and Puerto Rico. ISTA is a prescription eye care business in the United States and has an allergy drug franchise. ISTA manufactures its finished good products through third-party contracts. ISTA in-licenses or acquires new products and technologies to add to its internal development. Its products and product candidates seek to treat allergy and diseases of the eye and include therapies for ocular inflammation and pain, glaucoma, dry eye and ocular and nasal allergies. It has four products available for sale in the United States and Puerto Rico: BROMDAY (bromfenac ophthalmic solution) 0.09%, BEPREVE (bepotastine besilate ophthalmic solution) 1.5%, ISTALOL (timolol maleate ophthalmic solution) 0.5% and VITRASE (hyaluronidase injection).

Receive ISTA News and Ratings via Email

Sign-up to receive the latest news and ratings for ISTA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A


Outstanding SharesN/A

Ista Pharmaceuticals (NASDAQ:ISTA) Frequently Asked Questions

What is Ista Pharmaceuticals' stock symbol?

Ista Pharmaceuticals trades on the NASDAQ under the ticker symbol "ISTA."

Who are some of Ista Pharmaceuticals' key competitors?

Has Ista Pharmaceuticals been receiving favorable news coverage?

Media coverage about ISTA stock has trended positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ista Pharmaceuticals earned a news impact score of 0.39 on Accern's scale. They also assigned news coverage about the specialty pharmaceutical company an impact score of 45.19 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term.

How do I buy shares of Ista Pharmaceuticals?

Shares of ISTA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How can I contact Ista Pharmaceuticals?

Ista Pharmaceuticals' mailing address is #D1, 10574 Acacia Street, RANCHO CUCAMONGA, CA 91730, United States. The specialty pharmaceutical company can be reached via phone at +1-949-7886000.

MarketBeat Community Rating for Ista Pharmaceuticals (ISTA)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  56 (Vote Outperform)
Underperform Votes:  56 (Vote Underperform)
Total Votes:  112
MarketBeat's community ratings are surveys of what our community members think about Ista Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ista Pharmaceuticals (NASDAQ:ISTA) Analyst Ratings History

No equities research coverage for this company has been tracked by MarketBeat


Ista Pharmaceuticals (NASDAQ:ISTA) Earnings History and Estimates Chart

Earnings by Quarter for Ista Pharmaceuticals (NASDAQ:ISTA)

Ista Pharmaceuticals (NASDAQ ISTA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/3/2012($0.11)($0.43)ViewN/AView Earnings Details
2/23/2012$0.21$0.25ViewN/AView Earnings Details
11/1/2011$0.09$0.09ViewN/AView Earnings Details
7/28/2011$0.04($0.11)ViewN/AView Earnings Details
5/5/2011($0.15)($0.17)ViewN/AView Earnings Details
2/23/2011$0.09$0.14ViewN/AView Earnings Details
11/2/2010Q3 2010$0.04$0.08ViewN/AView Earnings Details
4/30/2010Q1 2010($0.12)($0.20)ViewN/AView Earnings Details
2/23/2010Q4 2009$0.03ViewN/AView Earnings Details
8/5/2009Q2 2009($0.09)($0.08)ViewN/AView Earnings Details
5/7/2009Q1 2009($0.19)($0.19)ViewN/AView Earnings Details
2/19/2009Q4 2008($0.09)($0.06)ViewN/AView Earnings Details
10/30/2008Q3 2008($0.23)($0.22)ViewN/AView Earnings Details
8/7/2008Q2 2008($0.29)($0.26)ViewN/AView Earnings Details
4/30/2008Q1 2008($0.38)($0.39)ViewN/AView Earnings Details
3/6/2008Q4 2007($0.28)($0.30)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Ista Pharmaceuticals (NASDAQ:ISTA) Earnings Estimates

No earnings estimates for this company have been tracked by


Dividend History for Ista Pharmaceuticals (NASDAQ:ISTA)

No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Ista Pharmaceuticals (NASDAQ ISTA)

No insider trades for this company have been tracked by


Ista Pharmaceuticals (NASDAQ ISTA) News Headlines

EU mergers and takeovers (Sept 27) - ReutersEU mergers and takeovers (Sept 27) - Reuters - September 28 at 12:09 PM

SEC Filings

Ista Pharmaceuticals (NASDAQ:ISTA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Ista Pharmaceuticals (NASDAQ:ISTA) Income Statement, Balance Sheet and Cash Flow Statement


Ista Pharmaceuticals (NASDAQ ISTA) Stock Chart for Wednesday, March, 21, 2018

Loading chart…

This page was last updated on 3/21/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.